Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.57
-4.8%
$2.25
$1.60
$16.55
$190.77M1.111.03 million shs587,171 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$4.91
+8.1%
$4.22
$0.66
$10.77
$49.21M-1.237.68 million shs90,544 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$2.95
+3.9%
$2.91
$2.36
$4.98
$220.66M0.42858,724 shs1.10 million shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$5.43
-0.9%
$5.42
$3.50
$7.55
$205.47M0.542,144 shs50,544 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+7.53%+0.39%+4.47%-81.38%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00%+3.15%+1,348.38%+376.70%+1,826.25%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
0.00%+17.06%-1.01%-17.37%-37.63%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
0.00%-2.34%+6.26%-3.89%-24.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.5078 of 5 stars
4.60.00.00.02.72.50.6
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.3652 of 5 stars
1.03.00.04.23.51.71.9
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.8823 of 5 stars
3.63.00.00.02.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.50386.38% Upside
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00
N/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.001.69% Upside
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
3.25
Buy$10.7597.97% Upside

Current Analyst Ratings Breakdown

Latest OBLN, OSUR, TLSI, and CATX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
4/7/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $10.00
3/31/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/28/2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/27/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00
3/26/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
3/19/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/17/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
3/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$1.43M133.40N/AN/A$2.67 per share0.96
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M30.95N/AN/A$0.60 per share8.18
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$161.63M1.37$1.02 per share2.89$5.86 per share0.50
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$32.14M6.39N/AN/A($0.98) per share-5.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/A-776.76%-161.38%-83.58%N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M-$0.4219.67N/AN/A5.07%3.55%3.23%8/5/2025 (Estimated)
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$59.04M-$1.12N/AN/AN/A-206.24%N/A-236.83%8/13/2025 (Estimated)

Latest OBLN, OSUR, TLSI, and CATX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million
3/27/2025Q4 2024
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.35-$0.35N/A-$0.40$8.12 million$8.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.60
11.20
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/A
2.40
2.00

Institutional Ownership

CompanyInstitutional Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
18.64%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million72.06 millionOptionable
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
10637.84 million20.49 millionNot Optionable

Recent News About These Companies

Roth Capital Issues Pessimistic Estimate for TLSI Earnings
Cantor Fitzgerald Has Negative View of TLSI FY2025 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$2.57 -0.13 (-4.81%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.57 0.00 (0.00%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Obalon Therapeutics stock logo

Obalon Therapeutics NASDAQ:OBLN

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$2.95 +0.11 (+3.87%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.88 -0.07 (-2.37%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

TriSalus Life Sciences stock logo

TriSalus Life Sciences NASDAQ:TLSI

$5.43 -0.05 (-0.91%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.00 -0.43 (-7.92%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.